Scholarlink

Objectives and background <p>The aim of the study was to evaluate the long-term effects of tafamidis on cardiac disease progression beyond 12&#xa0;months of treatment by performing (among others) serial multi-parametric cardiovascular magnetic resonance (CMR) studies in patients with transthyretin (ATTR) cardiac amyloidosis (CA) cardiomyopathy (ATTR-CM).</p> Methods <p>Patients with confirmed ATTR-CM (<i>N</i> = 56) were divided into two groups: in the larger group A (<i>N</i> = 39; 95% male), treatment with tafamidis 61&#xa0;mg once daily was initiated after the first CMR study, whereas group B (<i>N</i> = 17; 76% male) comprised ATTR-CM patients who did not receive tafamidis. The observational follow-up period lasted 27 ± 6&#xa0;months. During this period, patients underwent two multi-parametric CMR studies at our institution as part of a routine clinical observation pipeline.</p> Results <p>Clinical symptoms assessed by the NYHA class showed a slight, however, significant increase in both groups. NT-proBNP levels substantially increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B (<i>p</i> = 0.014). LV systolic function, defined by LV-EF and 3D global longitudinal peak strain, significantly worsened in both groups at follow-up (54% to 48% <i>p</i> &lt; 0.001 vs 56% to 46%, <i>p</i> &lt; 0.001; −7.4 to −5.3, <i>p</i> &lt; 0.001 vs −8.8 to −4.8, <i>p</i> &lt; 0.001). However, the tafamidis-naïve group B experienced a substantially higher impairment of both parameters when compared to group A (∆p = 0.008 and ∆p = 0.003, respectively). LV wall thickness considerably increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B (from 18.2&#xa0;mm to 21.1&#xa0;mm at follow-up, <i>p</i> &lt; 0.001) compared to the tafamidis-treated group A (from 18.5&#xa0;mm to 19.2&#xa0;mm, p = 0.012; ∆<i>p</i> &lt; 0.001). Both global native T1 and global ECV values were significantly elevated in both groups—at baseline and at follow-up—with a significant increase in both groups during follow-up. However, a substantially higher increase in global ECV was observed in the tafamidis-naïve group B compared to the tafamidis-treated group A (group A: 51% to 57%, <i>p</i> &lt; 0.001; group B: 50% to 67%, <i>p</i> &lt; 0.001; ∆p &lt; 0.001).</p> Conclusion <p>Substantial worsening of clinical symptoms, serum biomarkers, and imaging parameters occurred in both tafamidis-treated and tafamidis-naïve ATTR-CM patients within a follow-up period of approximately 2&#xa0;years. However, the “extent of worsening” is significantly lower in the tafamidis-treated compared to the tafamidis-naïve patients.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月27日

查看全文
  • Alexandru Zlibut,
  • Michael Bietenbeck,
  • Nuriye Akyol,
  • Volker Vehof,
  • Redouane Bouras,
  • Khuraman Isgandarova,
  • Claudia Meier,
  • Maria Theofanidou,
  • Philipp Stalling,
  • Ali Yilmaz

摘要

Objectives and background

The aim of the study was to evaluate the long-term effects of tafamidis on cardiac disease progression beyond 12 months of treatment by performing (among others) serial multi-parametric cardiovascular magnetic resonance (CMR) studies in patients with transthyretin (ATTR) cardiac amyloidosis (CA) cardiomyopathy (ATTR-CM).

Methods

Patients with confirmed ATTR-CM (N = 56) were divided into two groups: in the larger group A (N = 39; 95% male), treatment with tafamidis 61 mg once daily was initiated after the first CMR study, whereas group B (N = 17; 76% male) comprised ATTR-CM patients who did not receive tafamidis. The observational follow-up period lasted 27 ± 6 months. During this period, patients underwent two multi-parametric CMR studies at our institution as part of a routine clinical observation pipeline.

Results

Clinical symptoms assessed by the NYHA class showed a slight, however, significant increase in both groups. NT-proBNP levels substantially increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B (p = 0.014). LV systolic function, defined by LV-EF and 3D global longitudinal peak strain, significantly worsened in both groups at follow-up (54% to 48% p < 0.001 vs 56% to 46%, p < 0.001; −7.4 to −5.3, p < 0.001 vs −8.8 to −4.8, p < 0.001). However, the tafamidis-naïve group B experienced a substantially higher impairment of both parameters when compared to group A (∆p = 0.008 and ∆p = 0.003, respectively). LV wall thickness considerably increased in both groups at follow-up, however, with a significantly higher increase in the tafamidis-naïve group B (from 18.2 mm to 21.1 mm at follow-up, p < 0.001) compared to the tafamidis-treated group A (from 18.5 mm to 19.2 mm, p = 0.012; ∆p < 0.001). Both global native T1 and global ECV values were significantly elevated in both groups—at baseline and at follow-up—with a significant increase in both groups during follow-up. However, a substantially higher increase in global ECV was observed in the tafamidis-naïve group B compared to the tafamidis-treated group A (group A: 51% to 57%, p < 0.001; group B: 50% to 67%, p < 0.001; ∆p < 0.001).

Conclusion

Substantial worsening of clinical symptoms, serum biomarkers, and imaging parameters occurred in both tafamidis-treated and tafamidis-naïve ATTR-CM patients within a follow-up period of approximately 2 years. However, the “extent of worsening” is significantly lower in the tafamidis-treated compared to the tafamidis-naïve patients.

Graphical abstract